CytRx Closes SynthRx Deal

CytRx said this week that it has closed its deal to exclusively license its phase III sickle cell disease drug Flocor, as well as its OptiVax vaccine delivery technology, to SynthRx, a Houston-based startup firm founded and run by Robert Hunter, a CytRx co-founder and chairman of the University of Texas' department of pathology and laboratory medicine.

The assets were leftovers from the time before CytRx acquired Global Genomics and was repositioned as an RNAi therapeutics firm.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Aug
07
Sponsored by
Qiagen

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.